missing translation for 'onlineSavingsMsg'
Learn More

LY2857785, MedChemExpress

Product Code. 16471307
Encompass_Preferred
Click to view available options
Quantity:
2 mg
5 mg
10 mg
50 mg
100 mg
Unit Size:
100mg
10mg
2mg
50mg
5mg
This item is not returnable. View return policy

Product Code. 16471307

Brand: Medchem Express HY12293

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

MedChemExpress LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).

LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).

Specifications

Chemical Name or Material LY2857785
CAS 1619903-54-6
Color Off-White
Purity Grade Notes Research
Molecular Formula C26H36N6O
Quantity 50 mg
Solubility Information DMSO : 10 mg/mL (22.29 mM; Need ultrasonic)
SMILES CC(C1=C2C=C(C3=NC(N[C@H]4CC[C@H](NC5CCOCC5)CC4)=NC=C3)C=CC2=NN1C)C
Molecular Weight (g/mol) 448.6
Formula Weight 448.6
Percent Purity 97.0%
Grade Research
Physical Form Solid
For Use With (Application) Cancer-Kinase/protease
Show More Show Less

Research purposes only

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.